12/31/2020 6:41:48 AM
Axsome Therapeutics Begins ACCORD Phase 3 Trial Of AXS-05 In Alzheimer’s Disease Agitation
12/31/2020 6:06:22 AM
Axsome Therapeutics Announces Positive Results From Phase 3 MOVEMENT Trial Of AXS-07 In Acute Treatment Of Migraine
12/8/2020 6:02:59 AM
Axsome Therapeutics Reports Positive Results From COMET-SI Trial Of AXS-05 In Patients With Major Depressive Disorder
12/2/2020 6:10:10 AM
Axsome Therapeutics Announces Positive Results From Open-label Phase 2 COMET-TRD Trial Of AXS-05
12/1/2020 6:12:49 AM
Axsome Therapeutics Announces Positive Results From Phase 3 COMET Long-Term Trial And COMET-AU Trial Of AXS-05
9/24/2020 6:10:17 AM
Axsome: AXS-07 Demonstrated Faster, More Durable Relief Of Migraine Pain As Compared To Rizatriptan
9/21/2020 7:07:53 AM
Axsome Therapeutics Says Development Plan For AXS-12 For Treatment Of Narcolepsy Has Been Expedited
9/14/2020 6:03:13 AM
Axsome Therapeutics Presents New Data From GEMINI Phase 3 Trial With AXS-05
8/31/2020 7:10:35 AM
Axsome Therapeutics Confirms Pivotal Status And Advancement Of AXS-05 For Alzheimer’s Disease Agitation
8/28/2020 7:07:25 AM
Axsome To Present Efficacy And Safety Data From CONCERT Phase 2 Trial Of AXS-12
8/20/2020 7:11:07 AM
Axsome Therapeutics Completes Pre-NDA Meeting For AXS-07 For Acute Treatment Of Migraine; On Track To Submit NDA In Q4
7/13/2020 7:09:20 AM
Axsome Completes Successful FDA Pre-NDA Meeting For AXS-05
6/26/2020 7:06:26 AM
Axsome Therapeutics: FDA Grants Breakthrough Therapy Designation For AXS-05 For Alzheimer’s Disease Agitation